T Wagner, Gaetano Lardieri, Nichelle Santos, Jessica Umlauf, Vaughn Wagner
At PhilaDelic 2025, the most consequential question was not whether psychedelics can help people. It was whether U.S. healthcare can recognize, reimburse, and safely scale the kind of care these treatments actually require. The molecule is rarely the bottleneck. The bottleneck is coverage: the administrative, financial, and operational machinery that determines what becomes a routine benefit versus a boutique, cash-pay luxury.
Picture the moment that would make “psychedelic medicine” real for most people. It is not a headline or a breakthrough trial result. It is a patient—or a burned-out nurse, a city EMT, a teacher—opening a benefits portal during open enrollment and seeing what is actually covered, what is cash-pay, and what will become a financial cliff. That is where psychedelic care either becomes healthcare, or stays aspirational.
This is the missing chapter in most psychedelic reporting. Coverage hinges on unglamorous questions: how a therapy is coded, documented, staffed, risk-managed, and audited; whether a payer can write a defensible medical policy; whether clinics can sustain the workflow; and whether employers can purchase it as a benefit without inheriting clinical liability. Those operational details decide what counts as care at scale.
At the PhilaDelic 2025 Fall Forum, lead organizer T Peterson Wagner brought together clinicians, payers, employers, and operators to help fill in this gap. The same pattern kept surfacing: access grows when delivery becomes practical and intelligible, when someone turns a complex intervention into something a plan can buy, a network can deliver, and a claims system can process. Ketamine shows this dynamic in the clearest, most immediate way.
Photo courtesy of Cesar Wild via Unsplash.
Ketamine: Cheap Drug, Expensive Care
At the conference, Penn psychiatrist Michael Thase put it bluntly: ketamine costs “less than 50 cents a dose,” calling …
Read More
Author: High Times Contributors / High Times
